# Stage88 TP/Risk Balance Follow-up Review(88?④퀎 ?듭젅/?꾪뿕 洹좏삎 ?꾩냽 寃??

- run(?ㅽ뻾): `run88A_stage88_v41_tp_risk_balance_followup_review_v1`
- source_stage(?먯쿇 ?④퀎): `87_adapter_research__v41_tp_risk_balance_repair`
- source_stage87_closeout_commit(?먯쿇 87?④퀎 醫낅즺 而ㅻ컠): `025fbbdb0f1cc03bd0afb5705ca4e6f4db720a57`
- source_stage87_latest_commit(?먯쿇 87?④퀎 理쒖떊 而ㅻ컠): `8d4ae045c08abdbfa6742d945a22f706dc9890a6`
- external_verification_status(?몃? 寃利??곹깭): `completed_existing_stage87_evidence_reviewed`
- decision(?먯젙): `continue_drawdown_and_oos_early_repair_in_stage89`
- boundary(寃쎄퀎): `research_development_only_no_live_readiness_no_runtime_authority_no_operating_promotion_no_operating_reference_no_production_baseline_no_deployment`

Stage88(88?④퀎)????optimization(理쒖쟻??媛 ?꾨땲??review gate(寃??愿臾??? Effect(?④낵): Stage87(87?④퀎) 寃곌낵瑜?KPI(?듭떖?깃낵吏?? 湲곗??쇰줈留??먮룆?섍퀬, ?ㅼ쓬 ?섎━ 吏덈Ц???묎쾶 ?먮Ⅸ??

## KPI Read(KPI ?듭떖?깃낵吏???먮룆)

Stage87(87?④퀎)??best variant(理쒖꽑 蹂????`s87_v41_h3_risk475_gate08_sl215_tp38_cd10`?대떎.

| split(遺꾪븷) | PF(?섏씡 ?⑺꽣) | net(?쒖넀?? | DD%(?먯떎瑜? | expectancy(湲곕?媛? | cost stressed expectancy(鍮꾩슜 ?뺣컯 湲곕?媛? |
|---|---:|---:|---:|---:|---:|
| validation IS(寃利??대?) | 1.54 | 910.48 | 25.98 | 4.51 | 4.2073 |
| OOS(?쒕낯?? | 1.54 | 534.74 | 18.69 | 3.34 | 3.0421 |

Compared with Stage83 CD10(83?④퀎 CD10 鍮꾧탳), Stage87 best(87?④퀎 理쒖꽑????validation PF/net/DD(寃利??섏씡 ?⑺꽣/?쒖넀???먯떎瑜?瑜?紐⑤몢 媛쒖꽑?덇퀬 OOS PF/DD(?쒕낯???섏씡 ?⑺꽣/?먯떎瑜???議곌툑 媛쒖꽑?덈떎. Effect(?④낵): 吏湲??쒕㈃? 踰꾨┫ ?꾨낫媛 ?꾨땲???ㅼ쓬 ?섎━??anchor(湲곗???濡???媛移섍? ?덈떎.

Compared with 34D target surface(34D 紐⑺몴 ?쒕㈃ 鍮꾧탳), ?꾩쭅 遺議깊븯??

- PF gap(PF 李⑥씠): 1.54 vs 1.583157, ??`-0.0432`
- validation net gap(寃利??쒖넀??李⑥씠): 910.48 vs 987.60, `-77.12`
- validation DD excess(寃利??먯떎瑜?珥덇낵): 25.98 vs 12.909136, `+13.07`
- OOS early(?쒕낯??珥덈컲): net(?쒖넀?? 11.65, PF(?섏씡 ?⑺꽣) 1.0436濡??뉖떎.
- OOS mid concentration(?쒕낯??以묐컲 吏묒쨷): OOS net(?쒕낯???쒖넀??????64.9%媛 mid segment(以묎컙 援ш컙)??紐곕┛??

Effect(?④낵): Stage87(87?④퀎)??34D(34D)瑜??섏? 寃껋씠 ?꾨땲?? 34D(34D) 諛⑺뼢?쇰줈 媛??섎? ?덈뒗 以묎컙 媛쒖꽑?대떎.

## Judgment(?먯젙)

- proceed(吏꾪뻾): yes(??. Stage87 best(87?④퀎 理쒖꽑????Stage83 CD10(83?④퀎 CD10)蹂대떎 洹좏삎??醫뗭븘議뚮떎.
- complete(?꾨즺): no(?꾨땲??. DD(?먯떎瑜?媛 紐⑺몴?좊낫???믨퀬 OOS early(?쒕낯??珥덈컲)媛 ?덈Т ?뉖떎.
- next repair(?ㅼ쓬 ?섎━): Stage89(89?④퀎)??validation DD compression(寃利??먯떎瑜??뺤텞)怨?OOS early strengthening(?쒕낯??珥덈컲 媛뺥솕)????吏덈Ц?쇰줈留??ㅻ，??

## Evidence(洹쇨굅)

- comparison_csv(鍮꾧탳 CSV): `stages/88_adapter_research__v41_tp_risk_balance_followup_review/03_reviews/stage88_stage83_stage87_comparison.csv`
- segment_flags_csv(援ш컙 ?뚮옒洹?CSV): `stages/88_adapter_research__v41_tp_risk_balance_followup_review/03_reviews/stage88_stage87_segment_flags.csv`
- source_stage87_summary(?먯쿇 87?④퀎 ?붿빟): `stages/87_adapter_research__v41_tp_risk_balance_repair/03_reviews/stage87_v41_tp_risk_balance_summary.csv`
- source_stage87_segment(?먯쿇 87?④퀎 援ш컙): `stages/87_adapter_research__v41_tp_risk_balance_repair/03_reviews/stage87_segment_kpi_summary.csv`
- source_stage87_telemetry(?먯쿇 87?④퀎 ?붾젅硫뷀듃由?: `stages/87_adapter_research__v41_tp_risk_balance_repair/03_reviews/stage87_risk_atr_telemetry.csv`

Forbidden claims(湲덉? 二쇱옣): deployment(諛고룷), live readiness(?ㅺ굅??以鍮?, production baseline(?앹궛 湲곗???, operating promotion(?댁쁺 ?밴꺽), operating reference(?댁쁺 湲곗?), runtime authority(?고???沅뚯쐞), legacy inheritance(?덇굅???곸냽).
